Bicycle Therapeutics plc (BCYC)
Largest Insider Buys in Sector
BCYC Stock Price History Chart
BCYC Stock Performance
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, …
Insider Activity of Bicycle Therapeutics plc
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $931,751 worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $6.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $382.15M.
The last purchase of 500,000 shares for transaction amount of $7.67M was made by BAKER BROS. ADVISORS LP () on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Bicycle Therapeutics plc
| 2024-12-16 | 500,000 0.7341% | $15.34 | $7.67M | -1.39% | ||||
| 2024-12-13 | 985,397 1.3409% | $13.76 | $13.56M | +9.49% | ||||
| 2024-11-11 | Sale | CHIEF ACCOUNTING OFFICER | 4,944 0.0073% | $25.13 | $124,248 | -16.69% | ||
| 2024-10-03 | Sale | CHIEF EXECUTIVE OFFICER | 3,212 0.0044% | $22.26 | $71,499 | +3.45% | ||
| 2024-10-03 | Sale | CHIEF TECHNOLOGY OFFICER | 972 0.0013% | $22.26 | $21,637 | +3.45% | ||
| 2024-10-03 | Sale | CHIEF OPERATING OFFICER | 972 0.0013% | $22.26 | $21,637 | +3.45% | ||
| 2024-10-03 | Sale | CHIEF BUSINESS OFFICER | 972 0.0013% | $22.26 | $21,637 | +3.45% | ||
| 2024-10-03 | Sale | CHIEF ACCOUNTING OFFICER | 153 0.0002% | $22.26 | $3,406 | +3.45% | ||
| 2024-10-03 | Sale | CHIEF PROD & SUPPLY CHAIN OFF | 247 0.0003% | $22.26 | $5,498 | +3.45% | ||
| 2024-07-03 | Sale | CHIEF EXECUTIVE OFFICER | 3,194 0.0073% | $19.64 | $62,730 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF TECHNOLOGY OFFICER | 967 0.0022% | $19.64 | $18,992 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF OPERATING OFFICER | 967 0.0022% | $19.64 | $18,992 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF SCIENTIFIC OFFICER | 779 0.0018% | $19.64 | $15,300 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF BUSINESS OFFICER | 967 0.0022% | $19.64 | $18,992 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF ACCOUNTING OFFICER | 148 0.0003% | $19.64 | $2,907 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF PROD & SUPPLY CHAIN OFF | 246 0.0006% | $19.64 | $4,831 | 0.00% | ||
| 2024-04-11 | Sale | CHIEF PROD & SUPPLY CHAIN OFF | 257 0.0006% | $22.49 | $5,780 | +1.20% | ||
| 2024-04-03 | Sale | CHIEF EXECUTIVE OFFICER | 3,158 0.0076% | $23.81 | $75,192 | -2.36% | ||
| 2024-04-03 | Sale | CHIEF TECHNOLOGY OFFICER | 955 0.0023% | $23.81 | $22,739 | -2.36% | ||
| 2024-04-03 | Sale | CHIEF OPERATING OFFICER | 955 0.0023% | $23.81 | $22,739 | -2.36% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 9995274 14.4826% | $14.68 | 2 | 0 | ||
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 2.837% | $14.68 | 1 | 0 | <0.0001% |
| HARLAND DEBORAH | director | 1915275 2.7751% | $14.68 | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 2.7682% | $14.68 | 1 | 2 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 1875637 2.7177% | $14.68 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $123.08M | 9.94 | 4.94M | +176.07% | +$78.5M | 0.88 | |
| Deep Track Capital Lp | $86.91M | 7.02 | 3.49M | 0% | +$0 | 0.4 | |
| Paradigm BioCapital Advisors LP | $80.84M | 6.53 | 3.25M | -12.41% | -$11.46M | 2.93 | |
| Armistice Capital Llc | $41.63M | 3.36 | 1.67M | +8.85% | +$3.39M | 0.13 | |
| Tybourne Capital Management HK Ltd | $38.47M | 3.11 | 1.55M | -6.38% | -$2.62M | 6.58 |